Gilead Pays Tribute to Patient Advocacy Work: Cara’s Story
NORTHAMPTON, MA / ACCESSWIRE / January 10, 2024 / Gilead Sciences:When employees at Gilead's recently opened New Jersey office need...
Brain
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Correction: The initial release stated Mr. Peter Croden was previously Global President of Upjohn/Pfizer Animal Health Division in Germany. The...
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old...
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Athena will employ its successful history of securing government contracts, spearheading such initiativesJACKSON CENTER, PA / ACCESSWIRE / January 9,...
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity...
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust...
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven...
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever...
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations;...
Axial Therapeutics to Present at Upcoming Conferences
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
CervoMed to Participate in the Emerging Growth Conference 66
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approvedLONDON, Jan. 05,...
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”),...
Healthy Extracts Launches First Anti-Aging Formulation, LONGEVITY
LONGEVITY Anti-Aging™ BERGAMET’s New LONGEVITY Anti-Aging™ LAS VEGAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a...
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular...
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track...
Cognition Therapeutics CEO Issues Letter to Shareholders
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from...
Vensana Capital Strengthens Team with Promotions and Addition of Venture Partner
MINNEAPOLIS & WASHINGTON--(BUSINESS WIRE)--Vensana Capital, a leading medical technology-focused venture capital and growth equity investment firm, today announced the promotions...